Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H18NO2.Cl.H2O |
| Molecular Weight | 213.702 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Cl-].COC(=O)CCC[N+](C)(C)C
InChI
InChIKey=HUCARLCBGJLGMH-UHFFFAOYSA-M
InChI=1S/C8H18NO2.ClH.H2O/c1-9(2,3)7-5-6-8(10)11-4;;/h5-7H2,1-4H3;1H;1H2/q+1;;/p-1
DescriptionCurator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/22171995 and http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1602
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/22171995 and http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1602
Carpronium chloride is a hair growth reagent with a vasodilatory action. In vivo studies indicated that carpronium chloride achieved dilatation of vascular smooth muscle in the microcirculation of rats. FUROZIN SOLUTION 5% (active ingredient Carpronium chloride) has local vasodilating effect and hair growth stimulatory effect to improve alopecia and vitiligo. It is usually used for the prevention of hair loss, for hair growth stimulation, and in the treatment of seborrhea sicca and vitiligo vulgaris.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094109 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | FUROZIN SOLUTION 5% Approved UseUsed for the prevention of hair loss, for hair growth stimulation, and in the treatment of seborrhea sicca and vitiligo vulgaris. |
|||
| Primary | FUROZIN SOLUTION 5% Approved UseUsed for the prevention of hair loss, for hair growth stimulation, and in the treatment of seborrhea sicca and vitiligo vulgaris. |
|||
| Primary | FUROZIN SOLUTION 5% Approved UseUsed for the prevention of hair loss, for hair growth stimulation, and in the treatment of seborrhea sicca and vitiligo vulgaris. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies. | 2002 Oct |
|
| Study of active substances involved in skin dysfunction induced by crowding stress. I. Effect of crowding and isolation on some physiological variables, skin function and skin blood perfusion in hairless mice. | 2003 Feb |
|
| Effects of carpronium chloride on the microvascular blood flow in rat mesentery using intravital videomicroscopy. | 2006 |
|
| Topical immunotherapy in alopecia areata. | 2010 Jan |
Patents
Sample Use Guides
For alopecia and seborrhea sicca:
In general, apply appropriate amount of the medicine to the affected area; or sprinkle the medicine on the whole scalp; twice to 3 times daily, and gently massage the head.
For vitiligo vulgaris:
In general, apply appropriate amount of the medicine to the affected area, 3 to 4 times daily.
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
L4864ASJ91
Created by
admin on Sat Dec 16 05:26:04 GMT 2023 , Edited by admin on Sat Dec 16 05:26:04 GMT 2023
|
PRIMARY | |||
|
64675-20-3
Created by
admin on Sat Dec 16 05:26:04 GMT 2023 , Edited by admin on Sat Dec 16 05:26:04 GMT 2023
|
PRIMARY | |||
|
100000170620
Created by
admin on Sat Dec 16 05:26:05 GMT 2023 , Edited by admin on Sat Dec 16 05:26:05 GMT 2023
|
PRIMARY | |||
|
DTXSID60214949
Created by
admin on Sat Dec 16 05:26:04 GMT 2023 , Edited by admin on Sat Dec 16 05:26:04 GMT 2023
|
PRIMARY | |||
|
SUB184653
Created by
admin on Sat Dec 16 05:26:04 GMT 2023 , Edited by admin on Sat Dec 16 05:26:04 GMT 2023
|
PRIMARY | |||
|
45358895
Created by
admin on Sat Dec 16 05:26:05 GMT 2023 , Edited by admin on Sat Dec 16 05:26:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
